Intestinal Microbiota Detection for Cancer Relapse Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify and mitigate the risk of cancer relapse after hematopoietic stem cell transplantation (HSCT), particularly in relation to the intestinal microbiota composition.
Innovation Solution
Detection of specific bacteria such as Streptococcus anginosus, Parvimonas micra, Eubacterium limosum, and Enterococcus faecium in intestinal samples to assess the risk of cancer relapse, with therapeutic interventions involving probiotics, prebiotics, postbiotics, and antibiotics to modulate the microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used to assess cancer relapse risk, then the detection process is simple, but the ability to identify and mitigate relapse risk is insufficient
Solution Approach 1:
The patent introduces intestinal microbiota as an intermediary biomarker system to assess cancer relapse risk. Instead of directly detecting cancer cells or using complex imaging, the invention uses the composition of intestinal bacteria (specific genera such as Streptococcus, Parvimonas, Eubacterium, and Enterococcus) as a mediator to indirectly indicate relapse risk, thereby simplifying the detection approach while improving reliability
Solution Approach 2:
The patent replaces complex mechanical detection systems (such as imaging techniques or direct tissue biopsy) with a biochemical/diagnostic approach using molecular detection of bacterial DNA or RNA in stool samples. This substitution enables non-invasive risk assessment while maintaining high accuracy through specific microbial signature detection
2Reliability
If therapeutic interventions are implemented to modulate microbiota, then cancer relapse risk is reduced, but the complexity of treatment protocols increases
Solution Approach 1:
The patent applies parameter changes by modifying the microbial composition parameters of the intestinal microbiota through targeted therapeutic interventions. Specific probiotic strains are administered to alter bacterial abundance and diversity parameters, transforming the microbiota profile from a high-risk state to a protective state, thereby reducing cancer relapse risk through controlled biological parameter modification
Solution Approach 2:
The patent implements feedback mechanisms by monitoring changes in microbiota composition during therapy and adjusting treatment protocols accordingly. Patient-specific responses to probiotic interventions are tracked, and treatment strategies are dynamically modified based on observed microbial shifts and clinical outcomes, enabling personalized and adaptive therapy optimization
3Measurement precision
If detailed microbiota analysis is performed, then relapse risk assessment accuracy is improved, but the cost and time required for testing increases
Solution Approach 1:
The patent extracts and focuses analysis on specific bacterial genera known to be associated with cancer relapse risk (Streptococcus anginosus, Parvimonas micra, Eubacterium limosum, Enterococcus faecium). Instead of performing comprehensive whole-genome sequencing of all intestinal bacteria, the invention selectively targets and quantifies these specific microbial groups, thereby reducing testing time and cost while maintaining high measurement precision for risk assessment
Data Source
AI summary
The present invention relates to methods and compositions for reducing the risk of cancer relapse in a subject who has received cancer treatment. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Streptococcus anginosus, Parvimonas micra, Acidaminococcus intestini, Eubacterium limosum, Clostridium glycyrrhizinilyticum, Desulfosporosinus lacus, Eubacterium biforme, Anaerofustis stercorihominis, Pseudoramibacter alactolyticus, Peptococcus niger, Armatimonas rosea, Saccharofermentans acetigenes, Finegoldia magna, Levyella massiliensis, Gallicola barnesae, Murdochiella asaccharolytica, and Eubacterium brachy are associated with a reduced risk of cancer relapse.